Therefore, future research in a larger cohort is needed to elucidate the potentially beneficial effects of this supplement in dystroglycanopathy patients with an FKRP, FKTN, or ISPD mutation. The gene discussed is CRPPA; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.